ABSTRACT
BACKGROUND: Patients treated with total knee arthroplasty are at high risk for the development of venous thromboembolism postoperatively. This study compared the efficacy and safety of two common thromboprophylactic agents, enoxaparin (a low-molecular-weight heparin) and warfarin. METHODS: Three hundred and forty-nine patients were included in a prospective, randomized, multicenter, open-label, parallel-group clinical trial. Treatment with enoxaparin (30 mg, administered subcutaneously twice daily) or warfarin (adjusted to an international normalized ratio of 2 to 3) was initiated during the immediate postoperative period, within eight hours after the surgery, and was continued for four to fourteen days. Venous thromboembolism was defined as deep-vein thrombosis documented by contrast venography, symptomatic deep-vein thrombosis documented by lower-extremity ultrasonography, or symptomatic pulmonary embolism confirmed by a positive lung scan or pulmonary angiography. RESULTS: In the all-treated-patients group, eighty (45%) of the 176 warfarin-treated patients had venous thromboembolism: fifty-nine (34%) had distal deep-vein thrombosis; twenty (11%), proximal deep-vein thrombosis; and one (0.6%), pulmonary embolism. Venous thromboembolism developed in significantly fewer (p = 0.0001) enoxaparin-treated patients (forty-four of 173; 25%): forty-one (24%) had distal deep-vein thrombosis, three (2%) had proximal deep-vein thrombosis, and none had pulmonary embolism. The enoxaparin-treated patients also had a significantly lower prevalence of proximal deep-vein thrombosis (p = 0.002). The estimated odds for the development of venous thromboembolism were 2.52 times greater (95% confidence interval, 2.00 to 3.19) with warfarin than they were with enoxaparin. Major hemorrhage occurred in four warfarin-treated patients and nine enoxaparin-treated patients; with the numbers available, this difference was not significant (p = 0.17). Clinically important operative-site hemorrhage occurred in six (3%) of the warfarin-treated patients and twelve (7%) of the enoxaparin-treated patients (p = 0.15). CONCLUSIONS: A fixed 30-mg subcutaneous dose of enoxaparin, administered twice daily, with the first dose administered within eight hours after the completion of surgery, was significantly more effective than adjusted-dose warfarin in reducing the occurrence of asymptomatic venous thromboembolism, including proximal deep-vein thrombosis, in patients undergoing total knee arthroplasty. With the numbers available, there was no significant difference between groups with regard to the occurrence of major hemorrhagic complications; however, the rate of overall hemorrhagic complications was higher in the enoxaparin group.
Subject(s)
Anticoagulants/therapeutic use , Arthroplasty, Replacement, Knee/adverse effects , Enoxaparin/therapeutic use , Pulmonary Embolism/prevention & control , Venous Thrombosis/prevention & control , Warfarin/therapeutic use , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Enoxaparin/administration & dosage , Enoxaparin/adverse effects , Female , Hemorrhage/chemically induced , Humans , Male , Middle Aged , Postoperative Complications/prevention & control , Prospective Studies , Pulmonary Embolism/etiology , Treatment Outcome , Venous Thrombosis/etiology , Warfarin/administration & dosage , Warfarin/adverse effectsABSTRACT
BACKGROUND: Low-molecular-weight heparins administered subcutaneously once or twice daily have been reported to be as safe and efficacious as intravenous unfractionated heparin in the treatment of acute venous thromboembolic disease. OBJECTIVE: To determine whether subcutaneous enoxaparin administered once or twice daily is as effective as continuously infused unfractionated heparin in acute symptomatic venous thromboembolic disease. DESIGN: Randomized, controlled, partially blinded equivalence trial. SETTING: 74 hospitals in 16 countries. PATIENTS: 900 patients with symptomatic lower-extremity deep venous thrombosis, including 287 (32%) with confirmed pulmonary embolism. INTERVENTIONS: Initial therapy with dose-adjusted intravenous unfractionated heparin compared with subcutaneous enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily or 1.5 mg/kg once daily. Long-term oral anticoagulation was started in all patients within 72 hours of randomization. MEASUREMENTS: Clinical end points assessed during a 3-month follow-up period. RESULTS: Equivalent efficacy was seen in the heparin group and both enoxaparin groups. Symptomatic venous thromboembolism recurred in 12 of 290 patients receiving unfractionated heparin (4.1%), 13 of 298 patients receiving once-daily enoxaparin (4.4%), and 9 of 312 patients receiving twice-daily enoxaparin (2.9%). Compared with unfractionated heparin, the treatment difference was 0.2% (95% CI, -3.04% to 3.49%) for once-daily enoxaparin and -1.2% (CI, -4.2% to 1.7%) for twice-daily enoxaparin. Incidence of major hemorrhage did not differ among the three treatment groups. Major hemorrhage occurred in 6 of 290 patients (2.1%) in the unfractionated heparin group, 5 of 298 patients (1.7%) in the once-daily enoxaparin group, and 4 of 312 patients (1.3%) in the twice-daily enoxaparin group. CONCLUSIONS: Subcutaneous enoxaparin once or twice daily is as effective and safe as dose-adjusted, continuously infused unfractionated heparin in the prevention of recurrent symptomatic venous thromboembolic disease.
Subject(s)
Anticoagulants/administration & dosage , Enoxaparin/administration & dosage , Heparin, Low-Molecular-Weight/administration & dosage , Pulmonary Embolism/drug therapy , Venous Thrombosis/drug therapy , Administration, Cutaneous , Adolescent , Adult , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Drug Administration Schedule , Enoxaparin/adverse effects , Female , Follow-Up Studies , Hemorrhage/chemically induced , Heparin, Low-Molecular-Weight/adverse effects , Humans , Infusions, Intravenous , Male , Middle Aged , Pulmonary Embolism/complications , Recurrence , Risk Factors , Single-Blind Method , Thrombocytopenia/chemically induced , Treatment Outcome , Venous Thrombosis/complicationsABSTRACT
BACKGROUND: The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. OBJECTIVE: To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium). DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: 33 community, university, or university-affiliated hospitals. PATIENTS: 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. INTERVENTION: Daily subcutaneous ardeparin (100 anti-Xa IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. MEASUREMENTS: Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. RESULTS: Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% CI, 0.3 to 1.7]; P > 0.2; absolute difference, -0.56 percentage points [CI, -2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). CONCLUSIONS: Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2-percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for most patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.
Subject(s)
Ambulatory Care , Arthroplasty, Replacement, Hip/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Heparin, Low-Molecular-Weight/administration & dosage , Pulmonary Embolism/prevention & control , Thromboembolism/prevention & control , Venous Thrombosis/prevention & control , Adult , Aged , Cause of Death , Double-Blind Method , Drug Administration Schedule , Female , Hemorrhage/chemically induced , Heparin, Low-Molecular-Weight/adverse effects , Humans , Male , Middle Aged , Placebos , Pulmonary Embolism/etiology , Thrombocytopenia/chemically induced , Thromboembolism/etiology , Venous Thrombosis/etiologyABSTRACT
BACKGROUND: Subcutaneous low-molecular-weight heparin is at least as effective and safe as classic intravenous heparin therapy for the treatment of proximal vein thrombosis. Anticoagulant monitoring is not required with low-molecular-weight heparin. OBJECTIVE: To perform an economic evaluation of these therapeutic approaches by comparing cost and effectiveness. PATIENTS AND METHODS: A randomized trial in 432 patients with proximal vein thrombosis that compared intravenous heparin and low-molecular-weight heparin with objective documentation of clinical outcomes provided the opportunity to perform an analysis of cost-effectiveness to rank these alternative therapies in terms of both their cost and effectiveness. The economic viewpoint of this analysis was that of a third-party payer (ie, a ministry of health in Canada or an insurance company in the United States). RESULTS: In the intravenous heparin-treated group, the cost incurred for 100 patients was $414,655 (Canadian dollars) or $375,836 (US dollars), with a frequency of objectively documented venous thromboembolism of 6.9%. In the low-molecular-weight heparin-treated group, the cost incurred for 100 patients was $399,403 (Canadian dollars) or $335,687 (US dollars), with a frequency of objectively documented venous thromboembolism of 2.8%, thus providing a cost saving of $15,252 (Canadian dollars) or $40,149 (US dollars). Multiple sensitivity analyses were performed, and these procedures did not alter the findings of the study. CONCLUSIONS: The findings indicate that low-molecular-weight heparin therapy is at least as effective and safe but less costly than intravenous heparin treatment. The potential for outpatient therapy in up to 37% of patients who are receiving low-molecular-weight heparin would substantially augment the cost saving.
Subject(s)
Anticoagulants/economics , Heparin, Low-Molecular-Weight/economics , Heparin/economics , Thromboembolism/prevention & control , Thrombosis/drug therapy , Anticoagulants/administration & dosage , Bias , Canada , Cost-Benefit Analysis , Drug Administration Schedule , Heparin/administration & dosage , Heparin, Low-Molecular-Weight/administration & dosage , Humans , Infusions, Intravenous , Injections, Subcutaneous , Sensitivity and Specificity , Thromboembolism/etiology , Thrombosis/complications , Thrombosis/pathology , United StatesABSTRACT
BACKGROUND: Postoperative venous thrombosis and pulmonary embolism present a major clinical threat to patients undergoing total hip or knee arthroplasty. We performed an economic evaluation of warfarin sodium and subcutaneous low-molecular-weight heparin sodium prophylaxis comparing cost and effectiveness. METHODS: A consecutive series of 1436 patients who underwent hip or knee arthroplasty comparing these 2 regimens in a randomized trial with objective documentation of outcomes provided the opportunity to perform economic evaluations for Canada and the United States. RESULTS: Deep vein thrombosis was documented in 231 (37.4%) of 617 patients given warfarin and in 185 (31.4%) of 590 patients given low-molecular-weight heparin (P = .03). In Canada, warfarin and low-molecular-weight heparin (tinzaparin sodium) incurred costs per 100 patients of $11,598 and $9,197, respectively, providing a cost savings of $2,401 for the low-molecular-weight heparin group. The drug cost of low-molecular-weight heparin (tinzaparin) was $6 per day and for warfarin was $0.32 per day. Sensitivity analysis showed that low-molecular-weight heparin is more costly if drug costs are increased by 1.5-fold (ie, the cost of tinzaparin is increased from $6 per day to $8.82 per day or more). In the United States, the analysis was also not definitive; low-molecular-weight heparin was more costly than warfarin at drug costs of $15 and $2.01 per day, respectively. CONCLUSIONS: Our findings indicate that the decision to use low-molecular-weight heparin or warfarin prophylaxis in patients undergoing major joint replacement surgery is a finely tuned trade-off. Prophylaxis with low-molecular-weight heparin is equally or more effective than the more complex prophylaxis with warfarin. Major bleeding is uncommon but less frequent with warfarin use. The most significant parameters that influence the comparative cost-effectiveness are the cost of the drug, the cost of international normalized ratio monitoring, and the costs associated with major bleeding. The analysis also demonstrates that the results are health care system dependent (Canada vs US). In Canada, low-molecular-weight heparin (tinzaparin) is less costly because it avoids the need for international normalized ratio monitoring. In the United States, the drug cost for low-molecular-weight heparin will likely be the principal determinant of relative cost-effectiveness.
Subject(s)
Anticoagulants/economics , Heparin, Low-Molecular-Weight/economics , Hip Prosthesis/adverse effects , Knee Prosthesis/adverse effects , Thrombosis/economics , Thrombosis/prevention & control , Warfarin/economics , Adult , Aged , Anticoagulants/therapeutic use , Canada , Cost-Benefit Analysis , Double-Blind Method , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Injections, Subcutaneous , Male , Middle Aged , Thrombosis/etiology , United States , Warfarin/therapeutic useABSTRACT
This study was a randomized, parallel-group, open-label clinical trial comparing the efficacy and safety of Enoxaparin, a low-molecular-weight heparin, and unfractionated heparin to prevent deep venous thrombosis after elective total knee arthroplasty. Four hundred fifty-three patients were randomized and received study medications. The primary efficacy evaluation was unilateral contrast venography done at the end of study or earlier if clinically indicated. The primary safety outcome was the incidence of bleeding episodes. Patients were assigned to 1 of 2 postoperative treatment groups: Enoxaparin 30 mg subcutaneous every 12 hours (228 patients), or unfractionated heparin 5000 units subcutaneous every 8 hours (225 patients). The incidence of proximal and distal deep venous thrombosis in the Enoxaparin group was 24.6% (56/228), and in the heparin group 34.2% (77/225). Three major hemorrhagic episodes were observed in each treatment group. Two cases of pulmonary embolism occurred in patients receiving heparin (1 fatal); no cases occurred in patients receiving Enoxaparin. This study showed that Enoxaparin administered postoperatively 30 mg every 12 hours is more effective and as safe as unfractionated heparin prophylaxis to prevent deep venous thrombosis in patients having elective total knee arthroplasty.
Subject(s)
Anticoagulants/therapeutic use , Enoxaparin/therapeutic use , Heparin/therapeutic use , Knee Prosthesis , Thrombophlebitis/prevention & control , Aged , Enoxaparin/adverse effects , Female , Hemorrhage/chemically induced , Heparin/adverse effects , Humans , MaleABSTRACT
A randomized, parallel-group, open-label clinical trial (the physicians, patients, and staff were not blinded with regard to the regimen that had been used) was conducted, between December 1988 and September 1990, to compare the safety and efficacy of enoxaparin, a low-molecular-weight heparin, with the safety and efficacy of unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. Six hundred and ten patients were randomized, and 607 patients received one of the study medications. The evaluations of efficacy included contrast-media venography, non-invasive vascular examination, and clinical examination. Data on efficacy were available for 604 patients, who had been assigned to one of three treatment groups: thirty milligrams of enoxaparin every twelve hours (194 patients), forty milligrams of enoxaparin once daily (203 patients), or 5000 units of unfractionated heparin every eight hours (207 patients). All drugs were administered subcutaneously. Dosages were not adjusted on the basis of the results of coagulation tests or the body weight of the patient. Treatment was initiated within twenty-four hours after the operation and continued for a maximum of seven days. The primary safety outcome was the occurrence of bleeding episodes. An intent-to-treat patient analysis revealed that deep venous thrombosis occurred in nine (5 per cent) of the 194 patients who received thirty milligrams of enoxaparin every twelve hours, thirty (15 per cent) of the 203 patients who received forty milligrams of enoxaparin once daily, and twenty-four (12 per cent) of the 207 patients who received unfractionated heparin. The rate of deep venous thrombosis was significantly lower in the group that received thirty milligrams of enoxaparin every twelve hours than in the group that received unfractionated heparin (p = 0.03) and in the group that received forty milligrams of enoxaparin once daily (p = 0.0002). No clinically symptomatic pulmonary embolism was observed during the treatment or follow-up phase of this study in the group that received thirty milligrams of enoxaparin every twelve hours. Analysis of evaluable patients revealed a marked reduction in the rate of deep venous thrombosis in the group that received thirty milligrams of enoxaparin every twelve hours (eight [6 per cent] of 136 patients) compared with the group that received heparin (twenty-one [15 per cent] of 145 patients) (p = 0.10); however, this difference was not significant because of the small number of patients included in this analysis.(ABSTRACT TRUNCATED AT 400 WORDS)
Subject(s)
Enoxaparin/therapeutic use , Heparin/therapeutic use , Hip Prosthesis , Postoperative Complications/prevention & control , Thrombophlebitis/prevention & control , Aged , Alanine Transaminase/blood , Drug Administration Schedule , Enoxaparin/adverse effects , Female , Hemoglobins/analysis , Hemorrhage/chemically induced , Heparin/adverse effects , Humans , Injections, Subcutaneous , Male , Middle Aged , Phlebography , Thrombocytopenia/chemically induced , Thrombophlebitis/diagnosis , Treatment OutcomeABSTRACT
A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5-10 mg day-1; maximum 15 mg day-1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition of vitamin K and vitamin K epoxide was examined in the propositus, his two sisters and 13 control black male subjects. Each subject was given an i.v. bolus dose (5 mg) of vitamin K prior to and after 2 weeks of warfarin therapy (5 mg day-1). The oral clearances of (S)- and (R)-warfarin were also measured in each subject during the last day of warfarin therapy. The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy. The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects. In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively). In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).
Subject(s)
Warfarin/pharmacokinetics , Adult , Blood Coagulation/drug effects , Drug Resistance , Female , Humans , Male , Stereoisomerism , Vitamin K/pharmacokinetics , Vitamin K 1/analogs & derivatives , Vitamin K 1/pharmacokinetics , Warfarin/administration & dosage , Warfarin/pharmacologyABSTRACT
BACKGROUND: Low-molecular-weight heparin has a high bioavailability and a prolonged half-life in comparison with conventional unfractionated heparin. Limited data are available for low-molecular-weight heparin as compared with unfractionated heparin for the treatment of deep-vein thrombosis. METHODS: In a multicenter, double-blind clinical trial, we compared fixed-dose subcutaneous low-molecular-weight heparin given once daily with adjusted-dose intravenous heparin given by continuous infusion for the initial treatment of patients with proximal-vein thrombosis, using objective documentation of clinical outcomes. RESULTS: Six of 213 patients who received low-molecular-weight heparin (2.8 percent) and 15 of 219 patients who received intravenous heparin (6.9 percent) had new episodes of venous thromboembolism (P = 0.07; 95 percent confidence interval for the difference, 0.02 percent to 8.1 percent). Major bleeding associated with initial therapy occurred in 1 patient receiving low-molecular-weight heparin (0.5 percent) and in 11 patients receiving intravenous heparin (5.0 percent), a reduction in risk of 91 percent (P = 0.006). This apparent protection against major bleeding was lost during long-term therapy. Minor hemorrhagic complications were infrequent. Ten patients receiving low-molecular-weight heparin (4.7 percent) died, as compared with 21 patients receiving intravenous heparin (9.6 percent), a risk reduction of 51 percent (P = 0.049). CONCLUSIONS: Low-molecular-weight heparin is at least as effective and as safe as classic intravenous heparin therapy under the conditions of this study and more convenient to administer. The simplified therapy provided by low-molecular-weight heparin may allow patients with uncomplicated proximal deep-vein thrombosis to be cared for in an outpatient setting.
Subject(s)
Heparin/administration & dosage , Thrombophlebitis/drug therapy , Double-Blind Method , Female , Hemorrhage/chemically induced , Heparin/adverse effects , Humans , Infusions, Intravenous , Injections, Subcutaneous , Male , Middle Aged , Molecular Weight , Partial Thromboplastin Time , Recurrence , Risk , Thromboembolism/drug therapy , Thrombophlebitis/mortalityABSTRACT
Thirty-eight patients with Stage B2, C1 or C2 colon cancer (Astler-Coller Modification of Dukes) received 3000 rads whole abdominal radiation and concomitant intermittent bolus 5-FU as part of a phase I-II adjuvant trial. Patients whose tumor penetrated the serosa (B2 or C2) in addition received a 1600 rad boost to the tumor bed. 5-FU was administered only during radiation. It was given at a dose of 300 mg/m2 days 1-5 and 28-32 in 21 patients (Group A) and day 1-3 and 28-31 in 17 patients (Group B). Median follow-up time for Group A is 44 months. Group A patients have a disease-free survival of 66% and overall survival of 73% at 44 months. The 16 C2 patients in Group A have a disease-free survival of 54% and overall survival of 65% at 44 months. There was a 26% incidence of moderate to severe acute toxicity in Group A but no long term bowel, liver, or hematologic toxicity. One patient developed acute myelogenous leukemia 2 years after treatment. Group B patients had only a 6% incidence of moderate to severe toxicity, but had a disease-free survival of 60% and overall survival of 100% at median follow-up of 23 months. Group B Stage C2 patients had a disease-free survival of 53% and overall survival of 100% at this same follow-up period. Disease-free and overall survival in Group A Stage C2 patients is superior to that in several published trials. Given the manageable toxicity, adjuvant whole abdominal radiation with concomitant 5-FU and tumor bed boost should be tested in a randomized fashion for possible therapeutic benefits.
Subject(s)
Abdomen/radiation effects , Colonic Neoplasms/therapy , Fluorouracil/therapeutic use , Adult , Aged , Colonic Neoplasms/drug therapy , Colonic Neoplasms/radiotherapy , Combined Modality Therapy , Humans , Middle Aged , Pilot Projects , PrognosisSubject(s)
Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Combined Modality Therapy , Humans , Leukemia/diagnosis , Leukemia/therapy , Lymphoma/diagnosis , Lymphoma/therapy , TexasABSTRACT
The Coulter S+IV electronically generates an automated white blood cell differential which counts 10,000+ cells per sample, separating lymphocytes, mononuclear cells, and granulocytes. In patients with preleukemic or so-called myelodysplastic syndromes, the histograms are consistently abnormal. CBCs of five patients demonstrate the variable features of myelodysplasia involving abnormal monocytosis, neutropenia, thrombocytopenia, and macro-ovalocytic anemias. The histogram analysis of white blood cells is a rapid, economic way of alerting the hematologist to a possible diagnostic problem in the elderly patient population.
Subject(s)
Blood Cell Count/instrumentation , Myelodysplastic Syndromes/diagnosis , Adult , Aged , Aged, 80 and over , Bone Marrow Examination , Erythrocyte Count/instrumentation , Evaluation Studies as Topic , Female , Humans , Leukocyte Count/instrumentation , Male , Platelet Count/instrumentationSubject(s)
Anemia , Aged , Aging , Anemia/classification , Anemia/diagnosis , Anemia/physiopathology , HumansSubject(s)
Anticoagulants/therapeutic use , Thromboembolism/drug therapy , Anticoagulants/adverse effects , Anticoagulants/pharmacology , Aspirin/adverse effects , Aspirin/pharmacology , Aspirin/therapeutic use , Blood Platelets/drug effects , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/pharmacology , Fibrinolytic Agents/therapeutic use , Hemorrhage/chemically induced , Heparin/adverse effects , Heparin/pharmacology , Heparin/therapeutic use , Humans , Thromboembolism/etiology , Thromboembolism/prevention & control , Warfarin/adverse effects , Warfarin/pharmacology , Warfarin/therapeutic useABSTRACT
A case of fulminant hemolytic anemia associated with a leptospiral infection is presented with morphologic and erythrocyte lipid studies. Both the frequency and pathogenesis of anemia in human leptospirosis is poorly understood. The anemia frequently observed in Weil's syndrome has been ascribed on clinical impression to blood loss, renal failure, and/or an ill-defined hemolytic process. However, hemolytic anemia associated with leptospirosis in animals is well documented and is due to hemolysins with phospholipase activity. Our patient's erythrocyte morphologic abnormalities on bright light and electron microscopy included particles of cells and cells with a thorny or spiculated surface suggesting that the hemolytic process was due to membrane injury. Measurement of the erythrocyte membrane lipids showed reductions in sphingomyelin and phosphatidylethanolamine suggesting that the observed hemolysis and morphologic changes resulted from phospholipases produced by the infecting leptospirae.
Subject(s)
Anemia, Hemolytic/etiology , Leptospirosis/complications , Phospholipases/biosynthesis , Erythrocyte Membrane/analysis , Erythrocytes/pathology , Erythrocytes/ultrastructure , Humans , Leptospira/metabolism , Male , Membrane Lipids/analysis , Microscopy, Electron , Middle Aged , Phosphatidylethanolamines/analysis , Sphingomyelins/analysisSubject(s)
Antineoplastic Agents/therapeutic use , Inosine/analogs & derivatives , Leukemia/drug therapy , Acute Disease , Aldehydes/adverse effects , Aldehydes/therapeutic use , Antineoplastic Agents/adverse effects , Clinical Trials as Topic , Female , Humans , Inosine/adverse effects , Inosine/therapeutic use , MaleABSTRACT
Measurement of plasma levels of carcinoembryonic antigen, though not infrequently helpful in the mangement of patients with colorectal cancer, has serious limitations in terms of specificity and sensitivity. Many benign conditions may cause elevations of carcinoembryonic antigen, and even far advanced metastatic large bowel cancer may be associated with normal levels. Major treatment decisions should rarely, if ever, be based on plasma levels of carcinoembryonic antigen alone. Studies are currently underway to assess the value of serial levels of carcinoembryonic antigen in the early detection of recurrent disease with the hope of identifying patients who might be cured by secondary resections.
Subject(s)
Carcinoembryonic Antigen/analysis , Colonic Neoplasms/immunology , Rectal Neoplasms/immunology , Colonic Neoplasms/diagnosis , Colonic Neoplasms/therapy , Humans , Neoplasm Metastasis , Neoplasm Recurrence, Local , Prognosis , Rectal Neoplasms/diagnosis , Rectal Neoplasms/therapySubject(s)
Gastrointestinal Neoplasms/diagnosis , Lymphoma/diagnosis , Digestive System/diagnostic imaging , Digestive System Surgical Procedures , Gastrointestinal Neoplasms/pathology , Gastrointestinal Neoplasms/therapy , Gastroscopy , Humans , Lymphography , Lymphoma/pathology , Lymphoma/therapy , Radionuclide ImagingABSTRACT
An institutional experience with primary gastrointestinal lymphoma (PGL) is reviewed. Included are 46 cases involving the stomach, 11 involving the small bowel, and two, the large bowel. The clinical, pathologic, and therapeutic aspects of PGL are discussed.